Windlas Biotech appoints two independent directors, one resigns

Management Changes View source PDF Explain this filing

WINDLAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.6%Reaction day

₹945.50

prior close

₹950.30

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-1.8% vs market

Pharmaceuticals peers, median of 168sector-0.3%-1.3% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.0

10m

-3.0

15m

-3.5

30m

-2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.6+0.2-1.8-0.3-1.3

Next day

-3.3+0.9-4.2-0.3-3.0

-2.4-0.8-1.6-1.2-1.2

-3.5-0.1-3.4-1.0-2.5

-5.6-1.7-3.9-2.6-3.1

-6.1-4.3-1.8-3.8-2.3

-6.4-7.5+1.1-6.5+0.1

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Windlas Biotech's Board approved two new Independent Directors effective Oct 12, 2026, for five-year terms. Mr. Aashish Mehra (IIT Delhi, IIM Calcutta, 20+ years in pharma consulting) and Mr. Soni Saran Singh (Founder and CEO of NMTronics India, 30+ years in electronics manufacturing) join the Board, subject to shareholder approval. Mr. Vivek Dhariwal resigned as Independent Director and Board Chairman on the same day, citing personal reasons, and also stepped off the Nomination and Remuneration and CSR committees.

Likely market impact

Routine board refresh with industry experts replacing the outgoing Chairman. Largely neutral for shareholders; new appointments need shareholder approval.